Aline Frey

TL;DR: The risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo and there was no significant difference in mortality between the two study groups.

TL;DR: Clazosentan significantly decreased moderate and severe vasospasms in a dose-dependent manner and showed a trend for reduction in vasospasm-related morbidity/mortality in patients with aneurysmal subarachnoid hemorrhage when centrally assessed.

TL;DR: Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome and further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosetan in patients with aSAH.

TL;DR: The endothelin receptor antagonist tezosentan did not improve symptoms or clinical outcomes in patients with acute heart failure and was not associated with worse outcomes.

TL;DR: Clazosentan 15 mg/h significantly reduced postaSAH vasospasm-related morbidity/all-cause mortality; however, neither dose improved outcome (extended Glasgow Outcome Scale).